Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00065468
First received: July 24, 2003
Last updated: September 24, 2012
Last verified: September 2012
  Purpose

The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus], administered intravenously [IV] once weekly and the combination of CCI-779, administered IV once weekly with Interferon Alfa [IFN alfa] subcutaneously [SC] three times per week [TIW], compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in poor-prognosis subjects with advanced RCC.


Condition Intervention Phase
Carcinoma, Renal Cell
Kidney Neoplasms
Drug: Interferon Alfa
Drug: CCI-779
Drug: Interferon Alfa and CCI-779
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Three-Arm, Randomized, Open-Label Study Of Interferon Alfa Alone, CCI-779 Alone, And The Combination Of Interferon Alfa And CCI-779 In First-Line Poor-Prognosis Subjects With Advanced Renal Cell Carcinoma.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Baseline up to Month 80 ] [ Designated as safety issue: No ]
    Overall survival is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.


Secondary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: Baseline, monthly until tumor progression or death (up to Month 80) ] [ Designated as safety issue: No ]
    PFS based on Independent Central Review Assessment. The period from randomization until disease progression, death or date of last contact.

  • Percentage of Participants With Objective Response [ Time Frame: Baseline, every 2 months until tumor progression or death (up to Month 80) ] [ Designated as safety issue: No ]
    Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR was the disappearance of all target lesions and non target lesions. PR was at least a 30 percent (%) decrease in sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.

  • Percentage of Participants With Clinical Benefit [ Time Frame: Baseline, every 2 months until tumor progression or death (up to Month 80) ] [ Designated as safety issue: No ]
    Clinical benefit: confirmed CR or PR or had stable disease (SD) lasting at least 24 weeks. CR was the disappearance of all target lesions and non target lesions. PR was at least a 30% decrease in sum of the LD of target lesions, taking as reference the baseline sum LD. SD was having neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

  • Duration of Response (DR) [ Time Frame: Baseline, every month until tumor progression or death (up to Month 80) ] [ Designated as safety issue: No ]
    DR: Time from first documentation of objective tumor response to first date that recurrence or progressive disease (PD) was objectively documented, taking as a reference for PD, the smallest sum LD recorded since randomization.

  • Time to Treatment Failure (TTF) [ Time Frame: Baseline, every month until tumor progression or death (up to Month 80) ] [ Designated as safety issue: No ]
    TTF is defined as the time from the date of randomization to the date of PD or death, withdrawal from treatment due to an adverse event (AE), withdrawal of voluntary consent, or lost to follow-up, whichever occurred first, censored at the date of the conclusion of treatment phase.

  • Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) [ Time Frame: Baseline to Month 80 ] [ Designated as safety issue: Yes ]
    The Q-Twist is not a score calculated for each participant but is defined only on a by treatment group basis. For each treatment group, it is the weighted sum of the mean durations of the health states Tox, Twist, and Relapse. Tox is defined as time with severe toxicity related to treatment; Twist: time without symptoms or toxic side effects; and Relapse: time after relapse/progression. The mean duration of each health state is calculated based on the area under the Kaplan Meier curve pertaining to that health state. There is no direct method for calculating the "dispersion" of Q-Twist, and it is typically done using bootstrap method for purposes of inference (see, e.g., Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med 1990; 9: 1259-76). In practice, as apparently in the case with this study, the intermediate values resulting from the bootstrap exercise were not displayed.

  • European Quality of Life Health Questionnaire (EQ-5D) - Index Score [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. EQ-5D index measured 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Range of EQ-5D index score = -0.594 to 1 where higher scores indicated a better health state.


Enrollment: 626
Study Start Date: July 2003
Study Completion Date: March 2011
Primary Completion Date: June 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A Drug: Interferon Alfa
Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
Experimental: B Drug: CCI-779
25 mg of CCI-779 given Intra Venously once per week
Experimental: C Drug: Interferon Alfa and CCI-779
15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • This study will be conducted in subjects with histologically confirmed, advanced (stage IV or recurrent disease) RCC who have not received prior systemic therapy for their disease,

Exclusion Criteria:

  • Subjects with central nervous system (CNS) metastases
  • Prior anticancer therapy for RCC
  • Prior investigational therapy/agents within 4 weeks of randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065468

  Hide Study Locations
Locations
United States, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
United States, California
Pfizer Investigational Site
La Verne, California, United States, 91750
Pfizer Investigational Site
Los Angeles, California, United States, 90024-2828
Pfizer Investigational Site
San Diego, California, United States, 92123
Pfizer Investigational Site
San Francisco, California, United States, 94115
United States, Connecticut
Pfizer Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Florida
Pfizer Investigational Site
Boca Raton, Florida, United States, 33428
Pfizer Investigational Site
Miami, Florida, United States, 33136
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60612-3824
Pfizer Investigational Site
Urbana, Illinois, United States, 61801
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46303
Pfizer Investigational Site
South Bend, Indiana, United States, 46601
Pfizer Investigational Site
Terre Haute, Indiana, United States, 47802
United States, Kansas
Pfizer Investigational Site
Kansas City, Kansas, United States, 66160-7136
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
United States, Louisiana
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70121
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21231-1000
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0942
Pfizer Investigational Site
Detroit, Michigan, United States, 48202
United States, Missouri
Pfizer Investigational Site
Kansas City, Missouri, United States, 64131
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110
United States, Montana
Pfizer Investigational Site
Billings, Montana, United States, 59101
Pfizer Investigational Site
Great Falls, Montana, United States, 59405
United States, New Hampshire
Pfizer Investigational Site
Lebanon, New Hampshire, United States, 03766
United States, New Jersey
Pfizer Investigational Site
East Orange, New Jersey, United States, 07018
Pfizer Investigational Site
Morristown, New Jersey, United States, 07960
United States, New York
Pfizer Investigational Site
Bronx, New York, United States, 10466
Pfizer Investigational Site
New York, New York, United States, 10021
Pfizer Investigational Site
Rochester, New York, United States, 14642
Pfizer Investigational Site
Valhalla, New York, United States, 10595
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27710
Pfizer Investigational Site
Hickory, North Carolina, United States, 28602
United States, Ohio
Pfizer Investigational Site
Cleveland, Ohio, United States, 44195
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97213-2933
United States, Pennsylvania
Pfizer Investigational Site
Hershey, Pennsylvania, United States, 17033-0850
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29414
United States, Tennessee
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37920
Pfizer Investigational Site
Memphis, Tennessee, United States, 38120
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232-6310
United States, Texas
Pfizer Investigational Site
Houston, Texas, United States, 77030
United States, Utah
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84112
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23249
United States, Washington
Pfizer Investigational Site
Seattle, Washington, United States, 98101
Pfizer Investigational Site
Seattle, Washington, United States, 98109-1023
Argentina
Pfizer Investigational Site
Buenos, Aires, Argentina
Pfizer Investigational Site
San Miguel de Tucuman, Tucuman, Argentina, 4000
Pfizer Investigational Site
Buenos Aires, Argentina, C1426ANZ
Pfizer Investigational Site
Cordoba, Argentina, 5000
Pfizer Investigational Site
Mendoza, Argentina
Pfizer Investigational Site
Quilmes, Argentina
Pfizer Investigational Site
Unknown, Argentina
Australia, New South Wales
Pfizer Investigational Site
Kogarah, New South Wales, Australia, 2217
Pfizer Investigational Site
Newcastle, New South Wales, Australia
Pfizer Investigational Site
Westmead, New South Wales, Australia, 2145
Australia, South Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia, 5000
Australia, Victoria
Pfizer Investigational Site
Footscray, Victoria, Australia, 3012
Pfizer Investigational Site
Heidelberg, Victoria, Australia, 3084
Pfizer Investigational Site
Melbourne, Victoria, Australia, 3050
Canada, Alberta
Pfizer Investigational Site
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Pfizer Investigational Site
Kelowna, British Columbia, Canada, V1Y 5L3
Pfizer Investigational Site
Vancouver, British Columbia, Canada, V5Z 3J5
Canada, Manitoba
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R3E 0C9
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Pfizer Investigational Site
London, Ontario, Canada, N6A 4L5
Pfizer Investigational Site
Newmarket, Ontario, Canada, L3Y 2P9
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1H 8L6
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Canada, Quebec
Pfizer Investigational Site
Greenfield Park, Quebec, Canada, J4V 2H1
Pfizer Investigational Site
Montreal, Quebec, Canada, H2X 3J4
Pfizer Investigational Site
Montreal, Quebec, Canada, H2L 4M1
Pfizer Investigational Site
Montreal, Quebec, Canada, H3T 1E2
Pfizer Investigational Site
Quebec City, Quebec, Canada, G1R 2J6
Pfizer Investigational Site
Sherbrooke, Quebec, Canada, J1H 5N4
Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada, L8N 4A6
Czech Republic
Pfizer Investigational Site
Brno, Czech Republic, 656 53
Pfizer Investigational Site
Prague 5, Czech Republic, 150 00
Former Serbia and Montenegro
Pfizer Investigational Site
Sremska Kamenica, Novi Sad, Former Serbia and Montenegro, 21204
Germany
Pfizer Investigational Site
Bonn, NRW, Germany, 53105
Pfizer Investigational Site
Essen, NRW, Germany, 45122
Pfizer Investigational Site
Mainz, RP, Germany, D-55101
Greece
Pfizer Investigational Site
Heraklion, Creete, Greece
Pfizer Investigational Site
Patra, Greece
Hungary
Pfizer Investigational Site
Budapest, Hungary, H-1122
Italy
Pfizer Investigational Site
Roma, RM, Italy, 00144
Pfizer Investigational Site
Foggia, Italy, 71100
Pfizer Investigational Site
Milano, Italy, 20132
Latvia
Pfizer Investigational Site
Daugavpils, Latvia
Pfizer Investigational Site
Riga, Latvia, 1079
Pfizer Investigational Site
Riga, Latvia, 1002
Lithuania
Pfizer Investigational Site
Vilnius, Lithuania, 2021
Mexico
Pfizer Investigational Site
Monterrey, Nuevo Leon, Mexico, 64000
Pfizer Investigational Site
Leon Guanajuato, Mexico, 37000
Netherlands
Pfizer Investigational Site
Nijmegen, GA, Netherlands, 6525
Pfizer Investigational Site
Amsterdam, Netherlands, 1105 AZ
Pfizer Investigational Site
Enschede, Netherlands, 7511 JX
Poland
Pfizer Investigational Site
Bytom, Poland, 41-902
Pfizer Investigational Site
Lodz, Poland, 93-509
Pfizer Investigational Site
Lublin, Poland, 20-090
Pfizer Investigational Site
Olsztyn, Poland, 10-228
Pfizer Investigational Site
Opole, Poland, 45-060
Pfizer Investigational Site
Poznan, Poland, 61-878
Pfizer Investigational Site
Siedlce, Poland, 08-110
Pfizer Investigational Site
Warszawa, Poland, 00-909
Pfizer Investigational Site
Warszawa, Poland, 02-781
Russian Federation
Pfizer Investigational Site
Barnaul, Russian Federation, 656052
Pfizer Investigational Site
Kemerovo, Russian Federation, 650003
Pfizer Investigational Site
Moscow, Russian Federation, 125284
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Pfizer Investigational Site
Moscow, Russian Federation, 143423
Pfizer Investigational Site
Moscow, Russian Federation, 121356
Pfizer Investigational Site
Obninsk, Russian Federation, 249036
Pfizer Investigational Site
Saint Petersburg, Russian Federation, 188663
Pfizer Investigational Site
Saint Petersburg, Russian Federation, 197758
Pfizer Investigational Site
Saint Petersburg, Russian Federation
Pfizer Investigational Site
Saint Petersburg, Russian Federation, 194354
Pfizer Investigational Site
St Petersburg, Russian Federation, 197758
Pfizer Investigational Site
Ufa, Russian Federation, 450005
Pfizer Investigational Site
Ufa, Russian Federation
Serbia
Pfizer Investigational Site
Belgrade, Serbia, 11000
Slovakia
Pfizer Investigational Site
Banska Bystrica, Slovakia, 974 01
Pfizer Investigational Site
Bratislava, Slovakia, 833 10
Pfizer Investigational Site
Martin, Slovakia, 03659
Pfizer Investigational Site
Zlina, Slovakia, 012 07
South Africa
Pfizer Investigational Site
Port Elizabeth, Eastern Cape, South Africa, 6006
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa, 2197
Pfizer Investigational Site
Cape Town, South Africa, 7505
Pfizer Investigational Site
Gauteng, South Africa
Spain
Pfizer Investigational Site
Oviedo, Asturias, Spain, 33006
Pfizer Investigational Site
Badalona, Barcelona, Spain, 08916
Pfizer Investigational Site
Barcelona, Spain, 08025
Pfizer Investigational Site
Madrid, Spain, 28040
Sweden
Pfizer Investigational Site
Göteborg, Sweden, 41345
Pfizer Investigational Site
Stockholm, Sweden, 171 76
Pfizer Investigational Site
Uppsala, Sweden, 751 85
Taiwan
Pfizer Investigational Site
Taipei, ROC, Taiwan, 112
Pfizer Investigational Site
Taichung, Taiwan
Pfizer Investigational Site
Taipei, Taiwan, 104
Pfizer Investigational Site
Taoyuan, Taiwan, 333
Turkey
Pfizer Investigational Site
Istanbul, Turkey
Pfizer Investigational Site
Izmir, Turkey, 35100
Ukraine
Pfizer Investigational Site
Dnietropetrovsk, Ukraine
Pfizer Investigational Site
Donetsk, Ukraine, 83 092
Pfizer Investigational Site
Kharkov, Ukraine, 61 037
Pfizer Investigational Site
Kiev, Ukraine, 03 142
Pfizer Investigational Site
Lviv, Ukraine, 79031
Pfizer Investigational Site
Zaporozhye, Ukraine, 69103
United Kingdom
Pfizer Investigational Site
Manchester, Lancashire, United Kingdom, M20 4BX
Pfizer Investigational Site
Glasgow, Strathclyde, United Kingdom, G11 6NT
Pfizer Investigational Site
Sutton, Surrey, United Kingdom, SM2 5PT
Pfizer Investigational Site
Nottingham, United Kingdom, NG5 1PB
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00065468     History of Changes
Obsolete Identifiers: NCT00070330
Other Study ID Numbers: 3066K1-304
Study First Received: July 24, 2003
Results First Received: March 22, 2012
Last Updated: September 24, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Advanced Renal Cell Carcinoma
Kidney Cancer

Additional relevant MeSH terms:
Neoplasms
Carcinoma
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Adenocarcinoma
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Interferon-alpha
Interferons
Sirolimus
Everolimus
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents
Anti-Bacterial Agents
Antibiotics, Antineoplastic
Antifungal Agents
Immunosuppressive Agents

ClinicalTrials.gov processed this record on August 28, 2014